AU2008279778B2 - Method for Determining Insulin Sensitivity with Biomarkers - Google Patents

Method for Determining Insulin Sensitivity with Biomarkers Download PDF

Info

Publication number
AU2008279778B2
AU2008279778B2 AU2008279778A AU2008279778A AU2008279778B2 AU 2008279778 B2 AU2008279778 B2 AU 2008279778B2 AU 2008279778 A AU2008279778 A AU 2008279778A AU 2008279778 A AU2008279778 A AU 2008279778A AU 2008279778 B2 AU2008279778 B2 AU 2008279778B2
Authority
AU
Australia
Prior art keywords
metabolite
biomarkers
subject
hydroxybutyrate
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008279778A
Other languages
English (en)
Other versions
AU2008279778A1 (en
Inventor
Danny Alexander
Costel Chirila
Walter Gall
Yun Fu Hu
Kay Lawton
Michael Milburn
Matthew W. Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Publication of AU2008279778A1 publication Critical patent/AU2008279778A1/en
Priority to AU2014216035A priority Critical patent/AU2014216035B2/en
Application granted granted Critical
Publication of AU2008279778B2 publication Critical patent/AU2008279778B2/en
Priority to AU2016206265A priority patent/AU2016206265B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2008279778A 2007-07-17 2008-07-17 Method for Determining Insulin Sensitivity with Biomarkers Active AU2008279778B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2014216035A AU2014216035B2 (en) 2007-07-17 2014-08-22 Method for Determining Insulin Sensitivity with Biomarkers
AU2016206265A AU2016206265B2 (en) 2007-07-17 2016-07-19 Method for Determining Insulin Sensitivity with Biomarkers

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95028607P 2007-07-17 2007-07-17
US60/950,286 2007-07-17
US3762808P 2008-03-18 2008-03-18
US61/037,628 2008-03-18
PCT/US2008/008756 WO2009014639A2 (en) 2007-07-17 2008-07-17 Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014216035A Division AU2014216035B2 (en) 2007-07-17 2014-08-22 Method for Determining Insulin Sensitivity with Biomarkers

Publications (2)

Publication Number Publication Date
AU2008279778A1 AU2008279778A1 (en) 2009-01-29
AU2008279778B2 true AU2008279778B2 (en) 2014-09-18

Family

ID=40282019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008279778A Active AU2008279778B2 (en) 2007-07-17 2008-07-17 Method for Determining Insulin Sensitivity with Biomarkers

Country Status (9)

Country Link
US (5) US8187830B2 (enExample)
EP (1) EP2164977B1 (enExample)
JP (3) JP5701601B2 (enExample)
AU (1) AU2008279778B2 (enExample)
BR (1) BRPI0815095B1 (enExample)
CA (1) CA2690541A1 (enExample)
ES (1) ES2443540T3 (enExample)
MX (3) MX377928B (enExample)
WO (1) WO2009014639A2 (enExample)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011592D1 (de) * 2006-03-24 2011-02-10 Metanomics Gmbh MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II
WO2008015929A1 (fr) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. procédé d'évaluation de syndrome métabolique, appareil D'ÉVALUATION DE SYNDROME MÉTABOLIQUE, système D'ÉVALUATION DE SYNDROME MÉTABOLIQUE, programme d'évaluation de syndrome métabolique et support d'enregistrement, et proc&
US9867530B2 (en) 2006-08-14 2018-01-16 Volcano Corporation Telescopic side port catheter device with imaging system and method for accessing side branch occlusions
EP2172775A4 (en) * 2007-06-25 2010-12-01 Ajinomoto Kk METHOD OF EVALUATING VISCERAL GREASE ACCUMULATION
EP2178442B1 (en) 2007-07-12 2017-09-06 Volcano Corporation Catheter for in vivo imaging
US9596993B2 (en) 2007-07-12 2017-03-21 Volcano Corporation Automatic calibration systems and methods of use
US10219780B2 (en) 2007-07-12 2019-03-05 Volcano Corporation OCT-IVUS catheter for concurrent luminal imaging
BRPI0815095B1 (pt) 2007-07-17 2021-04-13 Metabolon, Inc Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo
EP2209001A4 (en) * 2007-10-25 2010-10-27 Ajinomoto Kk METHOD FOR ASSESSING STROKEN GLUCOSE TOLERANCE
EP2930512B1 (en) * 2007-11-02 2018-01-31 Metabolon, Inc. Biomarkers for fatty liver disease and methods using the same
CA2878025C (en) 2008-01-18 2018-12-11 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
EP2265957B1 (en) * 2008-04-09 2013-07-24 B.R.A.H.M.S GmbH Pro-endothelin-1 for the prediction of impaired peak oxygen consumption
US20100222315A1 (en) * 2008-09-24 2010-09-02 Harbor BioSciencs, Inc. Patient populations and treatment methods
EP2344890B1 (en) * 2008-10-20 2021-08-11 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods
US20110318726A1 (en) 2009-03-10 2011-12-29 Shah Svati H Predicting coronary artery disease and risk of cardiovascular events
WO2010114897A1 (en) * 2009-03-31 2010-10-07 Metabolon, Inc. Biomarkers related to insulin resistance and methods using the same
US10519504B2 (en) 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP2476053A4 (en) * 2009-09-08 2014-03-12 Nodality Inc ANALYSIS OF CELL NETWORKS
JP5787339B2 (ja) * 2009-12-28 2015-09-30 学校法人福岡大学 糖尿病前症の検査方法
JP2013522652A (ja) * 2010-03-23 2013-06-13 パーデュー・リサーチ・ファウンデーション 代謝物プロファイリングを用いた再発乳癌の早期検出
JP5801802B2 (ja) 2010-06-08 2015-10-28 カルピス株式会社 脂質代謝改善剤
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
KR20130041961A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액에서 질환 또는 상태의 특징을 검출하는 방법
CA2806301A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
WO2012012717A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
WO2012013667A1 (en) * 2010-07-30 2012-02-02 Technische Universität Graz Analyses of analytes by mass spectrometry with values in at least 3 dimensions
WO2012058298A1 (en) * 2010-10-26 2012-05-03 Mayo Foundation For Medical Education And Research Biomarkers of reduced insulin action
JP2014501926A (ja) * 2010-12-23 2014-01-23 メタノミクス ヘルス ゲーエムベーハー 糖尿病を予測する手段及び方法
US11141063B2 (en) 2010-12-23 2021-10-12 Philips Image Guided Therapy Corporation Integrated system architectures and methods of use
US11040140B2 (en) 2010-12-31 2021-06-22 Philips Image Guided Therapy Corporation Deep vein thrombosis therapeutic methods
WO2012116074A1 (en) * 2011-02-22 2012-08-30 Mayo Foundation For Medical Education And Research Biomarkers of insulin sensitivity
EP2694463B8 (en) 2011-04-04 2019-10-09 Berg LLC Treating central nervous system tumors with coenzyme q10
JP6260275B2 (ja) 2011-06-30 2018-01-17 味の素株式会社 脂肪肝の評価方法、脂肪肝評価装置、脂肪肝評価方法、脂肪肝評価プログラム、脂肪肝評価システム、および端末装置
EP3527990A1 (en) * 2011-07-28 2019-08-21 metanomics GmbH Use of sm_sphingomyelin (d18:1, c23:1) as a marker for heart failure
WO2013033592A1 (en) 2011-08-31 2013-03-07 Volcano Corporation Optical-electrical rotary joint and methods of use
JP6158186B2 (ja) * 2011-09-14 2017-07-05 メタボロン，インコーポレイテッド インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
WO2013122469A2 (en) * 2012-02-17 2013-08-22 Rijksuniversiteit Groningen Prediction of the efficacy of a medicament on renal or cardiovascular clinical outcomes
EP2642296A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. p-Cresol sulphate as biomarker for healthy ageing
EP2642294A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. Phenylacetylglutamine as biomarker for healthy ageing
EP2642295A1 (en) 2012-03-22 2013-09-25 Nestec S.A. 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing
EP2642293A1 (en) 2012-03-22 2013-09-25 Nestec S.A. 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing
EP2642297A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. Hydroxy-sphingomyelin 22:1 as biomarker for healthy ageing
ES2687979T3 (es) * 2012-06-05 2018-10-30 Nestec S.A. Métodos de diagnóstico de la enfermedad valvular crónica
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
KR20150035818A (ko) 2012-06-15 2015-04-07 해리 스타일리 순환 병든 세포를 사용하여 질환 또는 병태를 검출하는 방법
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
WO2014001451A1 (en) 2012-06-27 2014-01-03 Metanomics Health Gmbh Methods for identifying diabetes drugs
WO2014026991A1 (en) * 2012-08-13 2014-02-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Biomarkers for type 2 diabetes
US20140324460A1 (en) * 2012-09-26 2014-10-30 Health Diagnostic Laboratory, Inc. Method for determining and managing total cardiodiabetes risk
US9286673B2 (en) 2012-10-05 2016-03-15 Volcano Corporation Systems for correcting distortions in a medical image and methods of use thereof
US9292918B2 (en) 2012-10-05 2016-03-22 Volcano Corporation Methods and systems for transforming luminal images
US9858668B2 (en) 2012-10-05 2018-01-02 Volcano Corporation Guidewire artifact removal in images
US9307926B2 (en) 2012-10-05 2016-04-12 Volcano Corporation Automatic stent detection
US9367965B2 (en) 2012-10-05 2016-06-14 Volcano Corporation Systems and methods for generating images of tissue
US11272845B2 (en) 2012-10-05 2022-03-15 Philips Image Guided Therapy Corporation System and method for instant and automatic border detection
US10070827B2 (en) 2012-10-05 2018-09-11 Volcano Corporation Automatic image playback
US9324141B2 (en) 2012-10-05 2016-04-26 Volcano Corporation Removal of A-scan streaking artifact
US9478940B2 (en) 2012-10-05 2016-10-25 Volcano Corporation Systems and methods for amplifying light
US20140100454A1 (en) 2012-10-05 2014-04-10 Volcano Corporation Methods and systems for establishing parameters for three-dimensional imaging
US10568586B2 (en) 2012-10-05 2020-02-25 Volcano Corporation Systems for indicating parameters in an imaging data set and methods of use
US9840734B2 (en) 2012-10-22 2017-12-12 Raindance Technologies, Inc. Methods for analyzing DNA
EP2931132B1 (en) 2012-12-13 2023-07-05 Philips Image Guided Therapy Corporation System for targeted cannulation
CA2895502A1 (en) 2012-12-20 2014-06-26 Jeremy Stigall Smooth transition catheters
CA2895989A1 (en) 2012-12-20 2014-07-10 Nathaniel J. Kemp Optical coherence tomography system that is reconfigurable between different imaging modes
WO2014113188A2 (en) 2012-12-20 2014-07-24 Jeremy Stigall Locating intravascular images
US10942022B2 (en) 2012-12-20 2021-03-09 Philips Image Guided Therapy Corporation Manual calibration of imaging system
US11406498B2 (en) 2012-12-20 2022-08-09 Philips Image Guided Therapy Corporation Implant delivery system and implants
US10939826B2 (en) 2012-12-20 2021-03-09 Philips Image Guided Therapy Corporation Aspirating and removing biological material
JP2016501623A (ja) 2012-12-21 2016-01-21 アンドリュー ハンコック， 画像信号のマルチ経路処理のためのシステムおよび方法
US10058284B2 (en) 2012-12-21 2018-08-28 Volcano Corporation Simultaneous imaging, monitoring, and therapy
US9612105B2 (en) 2012-12-21 2017-04-04 Volcano Corporation Polarization sensitive optical coherence tomography system
CA2896004A1 (en) 2012-12-21 2014-06-26 Nathaniel J. Kemp Power-efficient optical buffering using optical switch
US10413317B2 (en) 2012-12-21 2019-09-17 Volcano Corporation System and method for catheter steering and operation
WO2014100606A1 (en) 2012-12-21 2014-06-26 Meyer, Douglas Rotational ultrasound imaging catheter with extended catheter body telescope
US9486143B2 (en) 2012-12-21 2016-11-08 Volcano Corporation Intravascular forward imaging device
CA2896006A1 (en) 2012-12-21 2014-06-26 David Welford Systems and methods for narrowing a wavelength emission of light
JP2016501625A (ja) 2012-12-21 2016-01-21 ジェローム マイ， 可変線密度での超音波撮像
CA2895993A1 (en) 2012-12-21 2014-06-26 Jason Spencer System and method for graphical processing of medical data
WO2014120449A1 (en) * 2013-01-31 2014-08-07 Metabolon, Inc. Biomarkers related to insulin resistance progression and methods using the same
RU2015136673A (ru) * 2013-01-31 2017-03-10 Каприон Протеомикс Инк. Биомаркеры сахарного диабета 2 типа и их применение
CN105120852A (zh) * 2013-02-14 2015-12-02 梅坦诺米克斯保健有限公司 评估生物样品质量的工具和方法
WO2014138555A1 (en) 2013-03-07 2014-09-12 Bernhard Sturm Multimodal segmentation in intravascular images
US10226597B2 (en) 2013-03-07 2019-03-12 Volcano Corporation Guidewire with centering mechanism
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
US20140276923A1 (en) 2013-03-12 2014-09-18 Volcano Corporation Vibrating catheter and methods of use
US10638939B2 (en) 2013-03-12 2020-05-05 Philips Image Guided Therapy Corporation Systems and methods for diagnosing coronary microvascular disease
US9301687B2 (en) 2013-03-13 2016-04-05 Volcano Corporation System and method for OCT depth calibration
EP2967488B1 (en) 2013-03-13 2021-06-16 Jinhyoung Park System for producing an image from a rotational intravascular ultrasound device
US11026591B2 (en) 2013-03-13 2021-06-08 Philips Image Guided Therapy Corporation Intravascular pressure sensor calibration
US20140278121A1 (en) * 2013-03-13 2014-09-18 Robust for Life, Inc. Systems and methods for network-based calculation and reporting of metabolic risk
US10292677B2 (en) 2013-03-14 2019-05-21 Volcano Corporation Endoluminal filter having enhanced echogenic properties
US10426590B2 (en) 2013-03-14 2019-10-01 Volcano Corporation Filters with echogenic characteristics
US12343198B2 (en) 2013-03-14 2025-07-01 Philips Image Guided Therapy Corporation Delivery catheter having imaging capabilities
US10219887B2 (en) 2013-03-14 2019-03-05 Volcano Corporation Filters with echogenic characteristics
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
CA2921530A1 (en) 2013-07-18 2015-01-22 True Health Diagnostics, Llc Method of determination of risk of 2 hour blood glucose equal to or greater than 140 mg/dl
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
GB2524230A (en) * 2014-02-14 2015-09-23 Asda Stores Ltd Transaction processing system and transaction processing method
EP4428251A3 (en) 2014-09-11 2024-12-18 Immunis.AI, Inc. Methods of detecting prostate cancer
WO2016103390A1 (ja) * 2014-12-25 2016-06-30 株式会社日立製作所 インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法
CN113156096A (zh) * 2015-01-09 2021-07-23 全球基因集团有限责任公司 用于诊断冠状动脉粥样硬化性疾病的基于血液的生物标志物
US10451641B2 (en) 2015-03-13 2019-10-22 Duke University Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction
JP6051258B2 (ja) * 2015-04-15 2016-12-27 ライオン株式会社 脂質異常症への罹患しやすさを試験する方法
KR101795689B1 (ko) * 2015-04-30 2017-11-30 경희대학교 산학협력단 혈관 협착 질환 진단용 마커 및 이의 용도
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
WO2018094204A1 (en) * 2016-11-17 2018-05-24 Arivale, Inc. Determining relationships between risks for biological conditions and dynamic analytes
US11881311B1 (en) 2017-02-17 2024-01-23 BioAge Labs, Inc. Survival prediction using metabolomic profiles
JP2018141728A (ja) * 2017-02-28 2018-09-13 トヨタ自動車株式会社 生活習慣病の診断方法
US11740247B2 (en) * 2017-11-22 2023-08-29 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating obesity
US20200041496A1 (en) * 2018-08-01 2020-02-06 Joshua Health Care LLC Methods for Identifying and Treating Mammalian Subjects with Insulin Resistance
JP7189537B2 (ja) * 2019-06-27 2022-12-14 サンスター株式会社 血液試料の酸化ｈｄｌ量の反映値を測定する工程を含む、測定方法
JP7665157B2 (ja) * 2019-07-08 2025-04-21 株式会社島津製作所 移植用肝臓の機能評価方法、移植用肝臓の機能評価プログラムおよび移植用肝臓の機能評価装置
WO2021072222A1 (en) * 2019-10-11 2021-04-15 The Regents Of The University Of California Metabolic profile screening for gestational diabetes
CN115552025A (zh) * 2020-02-05 2022-12-30 克利夫兰诊所基金会 基于苯乙酰谷氨酰胺水平的疾病检测和治疗
CN113866284B (zh) * 2020-06-30 2023-09-05 上海脉示生物技术有限公司 一组用于心力衰竭诊断的肠道微生物代谢标志物及其应用
CN112684064B (zh) * 2020-12-08 2022-05-17 安徽农业大学 用于筛选抗应激胁迫肉羊的血清代谢标志物及其应用
EP4262814A4 (en) * 2020-12-16 2025-02-26 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
CN113325117B (zh) * 2021-06-25 2022-07-15 中国医学科学院北京协和医院 一组生物标记物在制备预测静脉内平滑肌瘤病进展的试剂盒中的应用
CN115023608B (zh) * 2021-11-30 2024-01-19 江苏品生医疗科技集团有限公司 预测受试者患有糖尿病的可能性的标记物及其应用
JP2025504961A (ja) * 2022-01-28 2025-02-19 ジーエーティーシー ヘルス コーポレーション 糖尿病の早期発見のためのバイオマーカー
CN114965733B (zh) * 2022-04-07 2023-12-01 中国人民解放军总医院第一医学中心 结直肠进展期腺瘤诊断代谢标志物组合及其应用
WO2025019706A1 (en) * 2023-07-19 2025-01-23 Ahara Corporation Systems and methods for generating a nutrition program
CN119846232B (zh) * 2025-01-21 2025-10-03 宁夏农林科学院动物科学研究所(宁夏草畜工程技术研究中心) 一种早期诊断奶牛隐性乳房炎的生物标志物组合及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026458A1 (en) * 2004-12-17 2007-02-01 Entelos, Inc. Assessing insulin resistance using biomarkers

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
EP0825258A4 (en) * 1996-02-20 2001-12-05 Kyowa Hakko Kogyo Kk METHOD OF DETERMINING 1,5-ANHYDROGLUCITOL
JP2938048B1 (ja) * 1998-06-30 1999-08-23 技術研究組合医療福祉機器研究所 代謝機能測定装置
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
JP3975279B2 (ja) * 1999-11-01 2007-09-12 旭化成ファーマ株式会社 糖尿病予備群の検査方法
WO2001078652A2 (en) * 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2002011716A2 (en) * 2000-08-07 2002-02-14 Ranbaxy Signature Llc Liquid formulation of metformin
US20030092028A1 (en) * 2001-06-01 2003-05-15 Yuanhong Ma Methods and Reagents For Diagnosis and Treatment of Insulin Resistance and Related Condition
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
JP4100673B2 (ja) * 2001-12-07 2008-06-11 日本化薬株式会社 肝糖放出の検査方法
JP2003204800A (ja) * 2002-01-15 2003-07-22 Sumitomo Pharmaceut Co Ltd 糖代謝異常疾患マーカーおよびその利用
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
US20060148690A1 (en) * 2002-07-08 2006-07-06 Lydie Bougueleret Secreted peptides
JP2005006645A (ja) * 2003-05-22 2005-01-13 Sumitomo Chemical Co Ltd インスリン応答性の評価方法
WO2005094200A2 (en) * 2003-06-20 2005-10-13 University Of Florida Biomarkers for differentiating between type 2 and type 2 diabetes
US7345142B2 (en) * 2004-01-27 2008-03-18 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease
JP4547173B2 (ja) * 2004-03-17 2010-09-22 シスメックス株式会社 糖尿病診療支援システム
JP4533042B2 (ja) * 2004-08-25 2010-08-25 裕 笹川 糖尿病および糖代謝異常を判断する方法
WO2006036476A2 (en) * 2004-09-07 2006-04-06 The General Hospital Corporation Methods of detecting myocardial ischemia and myocardial infarction
JP4522222B2 (ja) * 2004-10-22 2010-08-11 扶桑薬品工業株式会社 血中脂肪酸濃度測定による心疾患の早期診断方法
WO2006063733A1 (en) * 2004-12-14 2006-06-22 F.Hoffmann-La Roche Ag Cd99 as target/marker for insulin resistance
JPWO2006073195A1 (ja) * 2005-01-07 2008-06-12 敏一 吉川 糖尿病の予知・診断方法および糖尿病予知・診断用キット
FR2890079B1 (fr) * 2005-08-26 2007-11-30 Alain Rambach Detection des salmonelles lactose +
JP2009509539A (ja) * 2005-09-30 2009-03-12 パーレジェン サイエンシーズ， インコーポレイテッド 血糖調節の障害のスクリーニングおよび処置のための方法および組成物
US20070218519A1 (en) * 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
JP2007127423A (ja) * 2005-10-31 2007-05-24 Toray Ind Inc ３−ヒドロキシ酪酸の測定方法およびキット
DE602007011592D1 (de) * 2006-03-24 2011-02-10 Metanomics Gmbh MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II
US8321154B2 (en) * 2007-03-26 2012-11-27 Bg Medicine, Inc. Methods for detecting coronary artery disease
BRPI0815095B1 (pt) 2007-07-17 2021-04-13 Metabolon, Inc Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo
WO2010114897A1 (en) * 2009-03-31 2010-10-07 Metabolon, Inc. Biomarkers related to insulin resistance and methods using the same
JP2014501926A (ja) * 2010-12-23 2014-01-23 メタノミクス ヘルス ゲーエムベーハー 糖尿病を予測する手段及び方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026458A1 (en) * 2004-12-17 2007-02-01 Entelos, Inc. Assessing insulin resistance using biomarkers

Also Published As

Publication number Publication date
MX341954B (es) 2016-09-08
ES2443540T3 (es) 2014-02-19
CA2690541A1 (en) 2009-01-29
US8546098B2 (en) 2013-10-01
BRPI0815095A2 (pt) 2017-05-09
US20120208215A1 (en) 2012-08-16
JP2016102797A (ja) 2016-06-02
US8809008B2 (en) 2014-08-19
MX377928B (es) 2025-03-10
JP2010537157A (ja) 2010-12-02
US20160178620A1 (en) 2016-06-23
EP2164977A4 (en) 2011-07-27
EP2164977A2 (en) 2010-03-24
MX2010000414A (es) 2010-04-01
JP2015064362A (ja) 2015-04-09
US8187830B2 (en) 2012-05-29
WO2009014639A3 (en) 2009-03-19
US10175233B2 (en) 2019-01-08
JP5701601B2 (ja) 2015-04-15
BRPI0815095B1 (pt) 2021-04-13
EP2164977B1 (en) 2013-10-30
US20130338031A1 (en) 2013-12-19
US9250225B2 (en) 2016-02-02
HK1142636A1 (en) 2010-12-10
WO2009014639A2 (en) 2009-01-29
US20150005195A1 (en) 2015-01-01
AU2008279778A1 (en) 2009-01-29
US20090155826A1 (en) 2009-06-18
JP5876918B2 (ja) 2016-03-02

Similar Documents

Publication Publication Date Title
AU2008279778B2 (en) Method for Determining Insulin Sensitivity with Biomarkers
US9910047B2 (en) Biomarkers related to insulin resistance progression and methods using the same
US20190120855A1 (en) Biomarkers for Fatty Liver Disease and Methods Using the Same
US20120122981A1 (en) Biomarkers Related to Insulin Resistance and Methods using the Same
JP6158186B2 (ja) インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
AU2016206265B2 (en) Method for Determining Insulin Sensitivity with Biomarkers
AU2014216035A1 (en) Method for Determining Insulin Sensitivity with Biomarkers
HK1142636B (en) Biomarkers for pre-diabetes and methods using the same
HK1217516B (en) Biomarkers related to insulin resistance progression and methods using the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)